Old metabolite with a genuinely interesting epigenetic aging angle, but thin human evidence and COI-clouded pilot data keep it mid-tier
Look, AKG has been sitting in the TCA cycle since the first organisms figured out oxidative metabolism. Calling it novel is a stretch. But there’s a specific modern angle that deserves a serious look: AKG is a required co-substrate for the 2-oxoglutarate-dependent dioxygenase (2-OGDD) superfamily, which includes TET enzymes driving DNA demethylation, JmjC-domain histone demethylases, and prolyl hydroxylases feeding into HIF pathway regulation. When plasma and tissue AKG levels fall with age, which they do, you’re potentially starving a set of enzymes that maintain epigenetic fidelity. That’s a real mechanistic hypothesis, not just “it’s in the Krebs cycle so it must be good.”
The animal data is what put Ca-AKG on the map for longevity researchers. The 2020 work (Shahmirzadi et al., Cell Metabolism) showed Ca-AKG supplementation at 2 percent chow concentration extended healthspan and lifespan in mice, with reduced senescence markers and attenuated inflammaging signals. The C. elegans results are older and show up to 50 percent lifespan extension, though worm data translates poorly. The mouse work is from a real lab with real methodology, but it’s essentially one study from one group at this point.
The human pilot is where things get complicated. Tian et al. 2022 (Aging journal, n=42, open-label) reported roughly 8 years of epigenetic age reduction using Horvath-type methylation clocks after Rejuvant supplementation. What we like: it’s actual human data with a pre-specified methylation endpoint, which is rare in this space. What we dont like: the study is from the Rejuvant commercial team, its open-label with no placebo arm, and epigenetic clocks as primary endpoints remain contested even among clock developers. Replicated, blinded data from independent groups simply doesnt exist yet.
As a bench tool, AKG has real utility for investigators studying 2-OGDD biology or aging-related epigenetic drift. If you’re running a research program on TET enzyme activity, substrate availability experiments are straightforward and informative. The compound is easy to source, stable, and inexpensive. That’s worth something, even if it’s not a sophisticated probe.
We think the 2-OGDD epigenetic aging story is the most interesting thing going on with this compound, and it’s underexplored relative to the NAD+/sirtuin and mTOR spaces that absorb most longevity research attention. But the honest assessment is that the human evidence is one small, conflict-laden pilot, and the mouse mechanism is incompletely worked out. This is a compound worth watching, not one to prioritize. If independent groups replicate the methylation clock findings in a blinded design, the score goes up meaningfully.